Nykode Therapeutics ASA (OL:NYKD) — Stock Price
Nykode Therapeutics ASA (OL:NYKD) is currently trading at Nkr3.59 NOK, down 0.55% today. Over the past 52 weeks, shares have ranged between Nkr1.64 and Nkr4.99. This page tracks Nykode Therapeutics ASA's live share price on the OL exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see cash flow conversion of Nykode Therapeutics ASA.
Nykode Therapeutics ASA (NYKD) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Nykode Therapeutics ASA's daily closing share price and trading volume on the OL exchange over the past year, giving a clear view of recent price momentum and liquidity.
Nykode Therapeutics ASA Income Statement — Revenue, Profit & Earnings by Year
Nykode Therapeutics ASA's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Nkr0.00 | Nkr8.68 Million | Nkr12.90 Million | Nkr7.17 Million | Nkr33.96 Million |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | Nkr8.68 Million | Nkr12.90 Million | Nkr7.17 Million | Nkr33.96 Million |
| Research & Development | Nkr13.40 Million | Nkr14.73 Million | Nkr29.36 Million | Nkr26.77 Million | Nkr16.30 Million |
| SG&A | Nkr13.55 Million | Nkr4.34 Million | Nkr6.28 Million | Nkr8.89 Million | Nkr9.28 Million |
| Total Operating Expenses | Nkr28.59 Million | Nkr57.01 Million | Nkr70.98 Million | Nkr60.32 Million | Nkr44.74 Million |
| Operating Income | Nkr-28.59 Million | Nkr-48.33 Million | Nkr-58.08 Million | Nkr-53.16 Million | Nkr-10.78 Million |
| EBITDA | — | Nkr-43.07 Million | Nkr-41.74 Million | Nkr-48.93 Million | Nkr-10.25 Million |
| EBIT | — | Nkr-45.33 Million | Nkr-43.86 Million | Nkr-50.74 Million | Nkr-10.99 Million |
| Interest Expense | Nkr125.00K | Nkr188.00K | Nkr224.00K | Nkr241.00K | Nkr130.00K |
| Income Before Tax | Nkr-17.70 Million | Nkr-45.51 Million | Nkr-44.09 Million | Nkr-50.98 Million | Nkr-11.12 Million |
| Income Tax Expense | — | Nkr-6.69 Million | Nkr-8.93 Million | Nkr-8.24 Million | Nkr-1.70 Million |
| Net Income | Nkr-12.24 Million | Nkr-38.82 Million | Nkr-35.15 Million | Nkr-42.74 Million | Nkr-9.41 Million |
Nykode Therapeutics ASA Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Nykode Therapeutics ASA's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Nkr99.95 Million | Nkr153.48 Million | Nkr208.19 Million | Nkr221.48 Million | Nkr265.56 Million |
| Total Current Assets | Nkr61.89 Million | Nkr117.07 Million | Nkr165.68 Million | Nkr211.87 Million | Nkr255.86 Million |
| Cash & Equivalents | Nkr60.29 Million | Nkr114.82 Million | Nkr161.95 Million | Nkr205.84 Million | — |
| Short-term Investments | — | — | — | Nkr0.00 | Nkr12.17 Million |
| Net Receivables | — | Nkr386.00K | Nkr0.00 | Nkr3.81 Million | Nkr25.30 Million |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | Nkr5.68 Million | Nkr7.74 Million | Nkr10.52 Million | Nkr9.53 Million | Nkr9.16 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Nkr8.42 Million | Nkr17.27 Million | Nkr36.93 Million | Nkr64.46 Million | Nkr71.50 Million |
| Total Current Liabilities | Nkr6.19 Million | Nkr9.10 Million | Nkr20.61 Million | Nkr38.98 Million | Nkr31.37 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | Nkr-111.38 Million | Nkr-156.23 Million | Nkr-200.33 Million | Nkr-208.59 Million |
| Total Stockholder Equity | Nkr91.54 Million | Nkr136.21 Million | Nkr171.26 Million | Nkr157.02 Million | Nkr194.06 Million |
| Retained Earnings | Nkr-2.53 Million | Nkr-8.76 Million | Nkr29.56 Million | Nkr64.71 Million | Nkr107.45 Million |
Nykode Therapeutics ASA Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Nykode Therapeutics ASA generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Nkr-29.46 Million | Nkr-51.22 Million | Nkr-96.62 Million | Nkr-20.69 Million | Nkr1.16 Million |
| Capital Expenditures | Nkr38.00K | Nkr71.00K | Nkr1.90 Million | Nkr2.67 Million | Nkr871.00K |
| Free Cash Flow | Nkr-29.49 Million | Nkr-51.29 Million | Nkr-98.53 Million | Nkr-23.37 Million | Nkr284.00K |
| Investing Cash Flow | Nkr3.52 Million | Nkr6.93 Million | Nkr7.04 Million | Nkr11.05 Million | Nkr10.75 Million |
| Financing Cash Flow | Nkr-33.60 Million | Nkr-1.40 Million | Nkr44.59 Million | Nkr360.00K | Nkr20.44 Million |
| Dividends Paid | Nkr32.28 Million | — | — | — | — |
| Stock-Based Compensation | Nkr-30.00K | Nkr3.79 Million | Nkr3.70 Million | Nkr3.83 Million | Nkr3.44 Million |
| Depreciation | Nkr2.04 Million | Nkr2.25 Million | Nkr2.12 Million | Nkr1.81 Million | Nkr734.00K |
| Change in Cash | Nkr-55.11 Million | Nkr-47.20 Million | Nkr-43.78 Million | Nkr-9.85 Million | Nkr32.38 Million |
Nykode Therapeutics ASA Earnings History — EPS Actual vs. Analyst Estimates
Track Nykode Therapeutics ASA's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 25, 2026 | — | — | — |
| Aug 26, 2026 | -0.21 | — | — |
| May 27, 2026 | -0.12 | — | — |
| Feb 25, 2026 | -0.25 | -0.25 | +1.12% |
| Nov 23, 2025 | -0.10 | -0.25 | +60.00% |
| Aug 27, 2025 | 0.03 | -0.23 | +111.78% |
| May 27, 2025 | -0.05 | -0.23 | +78.70% |
| Feb 26, 2025 | -0.22 | -0.68 | +67.65% |